Results 91 to 100 of about 43,170 (263)

Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi, Reimar W. Thomsen, Carina Lundby, Jacob Volmer Stidsen, Kurt Højlund, Jesper Ryg, Mette Reilev, Anton Pottegård   +7 more
wiley   +1 more source

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Sensor‐Detected Hypoglycaemia Is Associated With Inflammatory Protein and Immune Cell Alterations in People With Diabetes: Findings From the Hypo‐METRICS Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Experimental hypoglycaemia induces a persistent inflammatory response. We investigated whether real‐life sensor‐detected hypoglycaemia (SDH) is associated with immune parameters in people with Type 1 and Type 2 diabetes and explored potential differences between the groups.
Mandala Ajie, Namam Ali, Marijn S. Hendriksz, Patrick Divilly, Marloes J. Rietveld, Evertine J. Abbink, Pratik Choudhary, Julie Maria Bøggild Brøsen, Ulrik Pedersen‐Bjergaard, Rory J. McCrimmon, Mark Evans, Julia K. Mader, Bastiaan E. de Galan, Rinke Stienstra, Cees J. Tack, on behalf of the Hypo‐RESOLVE Consortium   +15 more
wiley   +1 more source

A DPP6‐Targeted PET Tracer for Non‐Invasive Imaging of Transplanted Human Islets

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Dipeptidyl peptidase‐like protein 6 (DPP6) is a potential molecular imaging biomarker for pancreatic and transplanted islets of Langerhans. 4hD29 is a single‐domain antibody with nanomolar affinity for DPP6. Here, we demonstrate the generation and validation of [68Ga]Ga‐NOTA‐4hD29 for Positron Emission Tomography (PET) imaging of ...
Amina Khalil, Arturo Roca‐Rivada, Svitlana Vasylovska, Lorenzo J. I. Balestri, Irina Velikyan, Sayro Jawurek, Alexandra C. Title, Burcak Yesildag, Luke R. Odell, Joey Lau, Decio L. Eizirik, Olof Eriksson   +11 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor [PDF]

, 2020
openaire   +1 more source

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran, Hyung‐Seok Kim, Rozalina G. McCoy, Zafar Zafari   +3 more
wiley   +1 more source

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose

Diabetes, Metabolic Syndrome and Obesity, 2014
Siddhartha Shankar Das, Hiroto Hayashi, Taiki Sato, Ren Yamada, Masahiro Hiratsuka, Noriyasu Hirasawa Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan ...
Das SS, Hayashi H, Sato T, Yamada R, Hiratsuka M, Hirasawa N   +5 more
doaj  

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). Materials and Methods This retrospective real‐world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic.
Maria Pompea Antonia Baldassarre, Giulia Di Dalmazi, Federica Carrieri, Giorgia Centorame, Luigi Piacentino, Sara Coluzzi, Gloria Formoso   +6 more
wiley   +1 more source

Genetics‐Informed Pharmacological Intervention in Gestational Diabetes Mellitus: Current Therapeutic Alignment, Emerging Targets and a Translational Roadmap

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Gestational diabetes mellitus (GDM) complicates roughly one in seven pregnancies and predicts later maternal type 2 diabetes mellitus (T2DM). Yet its pharmacological management still rests on a handful of agents (insulin, metformin and glibenclamide), none of them selected on the basis of the disease's molecular genetics.
Wael Osman
wiley   +1 more source

Dipeptidyl Peptidase 4 [PDF]

, 2020
openaire   +1 more source